BiotechTube

KPI-012 + KPI-012 Vehicle

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent Corneal Epithelial Defect

Conditions

Persistent Corneal Epithelial Defect

Trial Timeline

Feb 7, 2023 → Oct 19, 2025

NCT ID
NCT05727878

About KPI-012 + KPI-012 Vehicle

KPI-012 + KPI-012 Vehicle is a phase 2 stage product being developed by Kala Pharmaceuticals for Persistent Corneal Epithelial Defect. The current trial status is terminated. This product is registered under clinical trial identifier NCT05727878. Target conditions include Persistent Corneal Epithelial Defect.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05727878Phase 2Terminated

Competing Products

20 competing products in Persistent Corneal Epithelial Defect

See all competitors
ProductCompanyStageHype Score
E7777 9 mcg/kgEisaiPhase 3
77
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
33
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
52
AZD0837 + AspirinAstraZenecaPhase 2
52
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
23
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
52
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
85
CertoparinNovartisPhase 3
77
Omalizumab + PlaceboNovartisPhase 3
77
RivastigmineNovartisApproved
85
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 daysNovartisPhase 2
52
Indacaterol + Placebo to IndacaterolNovartisPhase 2
52
Omalizumab + PlaceboNovartisApproved
85
placebo + iv sildenafilPfizerPhase 3
76
etanercept + placeboPfizerPhase 2
51
SildenafilPfizerPhase 2
51
irbesartan + placeboSanofiApproved
84
iloprostBayerPre-clinical
20
IV Remodulin + PlaceboUnited TherapeuticsPhase 2
49

Other Products from Kala Pharmaceuticals

loteprednol etabonate 0.25% ophthalmic suspensionApproved
77
KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BIDPhase 3
69
KPI-121 1% + Prednisolone acetatePhase 3
69
KPI-121 Ophthalmic Suspension + VehiclePhase 3
69
KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic SuspensionPhase 3
69